Chemotherapy in Non‐seminomatous Testicular Tumours Stage I

Abstract

Chemotherapy improves the survival rate of patients with disseminated teratoid testicular tumours, but patients without evidence of metastatic spread are not usually given further treatment after retroperitoneal lymphadenectomy because of the high toxicity of most drugs; 10 to 20% of these patients die later with widespread disease. In an earlier series of 24 patients from our hospital the survival rate in stage I disease was below 70%. Since 1973, when we began to use adjuvant chemotherapy in this group, there have been no relapse.

Therapy in Stage I Non-Seminomatous Testicular Tumor

“…Thus, an interpre tation as to the effect in stage I (= A) is not possible. [12] consider adjuvant chemother apy with 6-9 courses of mitramycin necessary, having observed 30% (8/24) relapses after RLND, all of whom proved fatal. As the relapse rate and failure of salvage therapy are disproportionately high, they are unsuitable as basis for general recommendations.…”

Steroid Receptors in Urological Malignancies

“…Non-seminoma is less radiosensitive, extremely malignant and fast growing. In less advanced stages following orchiectomy, a radical lymph node dissection of the retroperitoneum is performed (63), possibly followed by adjuvant chemotherapy (28). Advanced cases can be successfully treated by chemotherapy, usually a combination of Velban, Rleomycin and Cis-diammino-dichloroplati-num (21).…”

Unilateral Retroperitoneal Lymph Node Dissection in Patients with Non-Seminomatous Testicular Tumor in Clinical Stage I

“…1971;Fraley et al, 1977;Johnson, 1977;Donohue et al, 1978;Skinner, 1978;Clements et al, 1981;Ekman and Edsmyr, 1981;Batata et al, 1982;Pontes et al. 1982;Raghavan et al, 1982;van der WerfMessing and Hop, 1982;Whitmore, 1982].…”